Skip to main content

 Related scientific articles (all)

Heterogeneity of dose distribution in normal tissues in case of radiopharmaceutical therapy with alpha-emitting radionuclides.

Authors : Li WB, Bouvier-Capely C, Saldarriaga Vargas C, Andersson M, Madas B
Year : 2022
Journal : Radiat Environ Biophys
Volume : 61
Pages : 579-596

Outcomes of patients with small and node-negative HER2-positive early breast cancer treated with adjuvant chemotherapy and anti-HER2 therapy-a sub-analysis of the ALTTO study.

Authors : Nader-Marta G, Debien V, Eiger D, Tsourti Z, Caparica R, Kassapian M, Napoleone S, Hultsch S, Korde L, Wang Y, Chumsri S, Pritchard KI, Untch M, Bellet-Ezquerra M, Dornelles Rosa D, Moreno-Aspitia A, Piccart M, Dafni U, de Azambuja E
Year : 2022
Journal : Br J Cancer
Volume : 127
Pages : 1799-1807

Effect of Prior Therapy and Disease Refractoriness on the Efficacy and Safety of Oral Selinexor in Patients with Diffuse Large B-cell Lymphoma (DLBCL): A Post-hoc Analysis of the SADAL Study.

Authors : Schuster M, Zijlstra J, Casasnovas RO, Vermaat JSP, Kalakonda N, Goy A, Choquet S, Neste EVD, Hill B, Thieblemont C, Cavallo F, De la Cruz F, Kuruvilla J, Hamad N, Jaeger U, Caimi P, Gurion R, Warzocha K, Bakhshi S, Sancho JM, Follows G, Egyed M, Offner F, Vassilakopoulos T, Samal P, Ku M, Ma X, Corona K, Chamoun K, Shah J, Shacham S, Kauffman MG, Canales M, Maerevoet M
Year : 2022
Journal : Clin Lymphoma Myeloma Leuk
Volume : 22
Pages : 483-494

Oncological outcomes of radical prostatectomy in very high-risk patients according to STAMPEDE criteria: does local treatment alone still have a place in the era of intensified systemic therapies?

Authors : Baboudjian M, Touzani A, Martini A, Diamand R, Roche JB, Lacetera V, Beauval JB, Gondran-Tellier B, Roumeguère T, Simone G, Windisch O, Benamran D, Fourcade A, Fiard G, Van Den Bergh RC, Peltier A, Ploussard G
Year : 2022
Journal : Minerva Urol Nephrol

Toward Targeted Therapies in Oesophageal Cancers: An Overview.

Authors : Bregni G, Beck B
Year : 2022
Journal : Cancers (Basel)
Volume : 14

Post-Neoadjuvant Treatment Strategies for Patients with Early Breast Cancer.

Authors : Agostinetto E, Jacobs F, Debien V, De Caluwé A, Pop CF, Catteau X, Aftimos P, de Azambuja E, Buisseret L
Year : 2022
Journal : Cancers (Basel)
Volume : 14

Efficacy of pharmacologic treatment for treating gastrointestinal angiodysplasias-related bleeding: a systematic review and meta-analysis.

Authors : Gkolfakis P, Fostier R, Tziatzios G, Lazaridis N, Fernandez Y Viesca M, Facciorusso A, Despott E, Triantafyllou K, Devière J, Arvanitakis M
Year : 2022
Journal : Eur J Gastroenterol Hepatol
Volume : 34
Pages : 1021-1030

Immune Cell Density Evaluation Improves the Prognostic Values of Staging and p16 in Oropharyngeal Cancer.

Authors : Descamps G, Furgiuele S, Mhaidly N, Journe F, Saussez S
Year : 2022
Journal : Cancers (Basel)
Volume : 14

Lurbinectedin in patients with pretreated neuroendocrine tumours: Results from a phase II basket study.

Authors : Longo-Muñoz F, Castellano D, Alexandre J, Chawla SP, Fernández C, Kahatt C, Alfaro V, Siguero M, Zeaiter A, Moreno V, Sanz-García E, Awada A, Santaballa A, Subbiah V
Year : 2022
Journal : Eur J Cancer
Volume : 172
Pages : 340-348

Real-world effectiveness of palbociclib plus fulvestrant in advanced breast cancer: Results from a population-based cohort study.

Authors : Cardoso Borges F, Alves da Costa F, Ramos A, Ramos C, Bernardo C, Brito C, Mayer-da-Silva A, Furtado C, Ferreira AR, Martins-Branco D, Miranda A, Lourenço A
Year : 2022
Journal : Breast
Volume : 62
Pages : 135-143

Outcome without any adjuvant systemic treatment in stage I ER+/HER2- breast cancer patients included in the MINDACT trial.

Authors : Lopes Cardozo JMN, Byng D, Drukker CA, Schmidt MK, Binuya MA, van t Veer LJ, Cardoso F, Piccart M, Smorenburg CH, Poncet C, Rutgers EJT
Year : 2022
Journal : Ann Oncol
Volume : 33
Pages : 310-320

First-in-human phase 1 dose-escalation study of CAN04, a first-in-class interleukin-1 receptor accessory protein (IL1RAP) antibody in patients with solid tumours.

Authors : Robbrecht D, Jungels C, Sorensen MM, Spanggaard I, Eskens F, Fretland SØ, Guren TK, Aftimos P, Liberg D, Svedman C, Thorsson L, Steeghs N, Awada A
Year : 2022
Journal : Br J Cancer
Volume : 126
Pages : 1010-1017

Pathological features of Prostate Imaging Reporting and Data System (PI-RADS) 3 MRI lesions in biopsy and radical prostatectomy specimens.

Authors : Rahota RG, Diamand R, Malavaud B, Fiard G, Descotes JL, Peltier A, Beauval JB, Roumeguère T, Roumiguié M, Albisinni S, Ploussard G
Year : 2022
Journal : BJU Int
Volume : 129
Pages : 621-626

Psychological factors associated with clinical fear of cancer recurrence in breast cancer patients in the early survivorship period.

Authors : Waroquier P, Delevallez F, Razavi D, Merckaert I
Year : 2022
Journal : Psychooncology
Volume : 31
Pages : 1877-1885

Use of information and communication technologies (ICTs) in cancer multidisciplinary team meetings: an explorative study based on EU healthcare professionals.

Authors : Prades J, Coll-Ortega C, Dal Lago L, Goffin K, Javor E, Lombardo C, de Munter J, Ponce J, Regge D, Salazar R, Valentini V, Borras JM
Year : 2022
Journal : BMJ Open
Volume : 12
Pages : e051181

The Managing Advanced Cancer Pain Together (MACPT) conversation tool: an evaluation of use in clinical practice.

Authors : Quinn B, Laurent S, Dargan S, Lapuente M, Lüftner D, Drudge-Coates L, Palma MD, Dal Lago L, Flynn J, Panter C, Seesaghur A
Year : 2022
Journal : Pain Manag
Volume : 12
Pages : 435-446

The Use of Pan-Tropomyosin Receptor Kinase Immunohistochemistry as a Screening Tool for the Detection of Neurotrophic Tropomyosin-Related Kinase Fusions: Real-World Data from a National Multicentric Retrospective Study.

Authors : Van Bockstal MR, Beniuga G, Craciun L, Creytens D, Dedeurwaerdere F, Delvenne P, Demetter P, De Wiest B, Dewinne K, Habran L, Pauwels P, Theate I, Vander Borght S, Van Der Steen K, Weynand B
Year : 2022
Journal : Pathobiology
Pages : 1-14

Corrigendum to 'p53 Reactivation by PRIMA-1Met (APR-246) sensitises V600E/KBRAF melanoma to vemurafenib'[Eur J of Cancer 55 (2016) 98-110].

Authors : Krayem M, Journe F, Wiedig M, Morandini R, Najem A, Salès F, Van Kempen LC, Sibille C, Awada A, Marine JC, Ghanem G
Year : 2022
Journal : Eur J Cancer
Volume : 175
Pages : 336-338

A Rare Case of Hepatic Vanishing Bile Duct Syndrome Occurring after Combination Therapy with Nivolumab and Cabozantinib in a Patient with Renal Carcinoma.

Authors : Gourari K, Catherine J, Garaud S, Kerger J, Lepida A, Georgala A, Lebrun F, Gomez Galdon M, Gil T, Willard-Gallo K, Langouo Fontsa M
Year : 2022
Journal : Diagnostics (Basel)
Volume : 12

Implication of body mass index (BMI) on the biological and clinical effects of endocrine therapy plus abemaciclib as neoadjuvant therapy for early breast cancer patients.

Authors : Franzoi MA, Lambertini M, Ceppi M, Bruzzone M, de Azambuja E
Year : 2022
Journal : Breast Cancer Res Treat
Volume : 192
Pages : 457-462